[1] Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003; 349: 583−596. doi: 10.1056/NEJMra023144 [2] [3] Masri A, Bukhari S, Eisele YS, et al. Molecular imaging of cardiac amyloidosis. J Nucl Med 2020; 61: 965−970. doi: 10.2967/jnumed.120.245381 [4] González-López E, Gallego-Delgado M, Guzzo-Merello G, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J 2015; 36: 2585−2594. doi: 10.1093/eurheartj/ehv338 [5] Castaño A, Narotsky DL, Hamid N, et al. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J 2017; 38: 2879−2887. doi: 10.1093/eurheartj/ehx350 [6] Maurizi N, Rella V, Fumagalli C, et al. Prevalence of cardiac amyloidosis among adult patients referred to tertiary centres with an initial diagnosis of hypertrophic cardiomyopathy. Int J Cardiol 2020; 300: 191−195. doi: 10.1016/j.ijcard.2019.07.051 [7] Tanskanen M, Peuralinna T, Polvikoski T, et al. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study. Ann Med 2008; 40: 232−239. doi: 10.1080/07853890701842988 [8] Ravichandran S, Lachmann HJ, Wechalekar AD. Epidemiologic and survival trends in amyloidosis, 1987-2019. N Engl J Med 2020; 382: 1567−1568. doi: 10.1056/NEJMc1917321 [9] Kyle RA, Linos A, Beard CM, et al. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood 1992; 79: 1817−1822. doi: 10.1182/blood.V79.7.1817.1817 [10] Shi J, Guan J, Jiang B, et al. Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway. Proc Natl Acad Sci U S A 2010; 107: 4188−4193. doi: 10.1073/pnas.0912263107 [11]

Palladini G, Hegenbart U, Milani P, et al. A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood 2014; 124: 2325−2332.

[12] Grogan M, Scott CG, Kyle RA, et al. Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol 2016; 68: 1014−1020. doi: 10.1016/j.jacc.2016.06.033 [13] Pilebro B, Suhr OB, Näslund U, et al. (99m)Tc-DPD uptake reflects amyloid fibril composition in hereditary transthyretin amyloidosis. Ups J Med Sci 2016; 121: 17−24. doi: 10.3109/03009734.2015.1122687 [14] Buxbaum J, Jacobson DR, Tagoe C, et al. Transthyretin V122I in African Americans with congestive heart failure. J Am Coll Cardiol 2006; 47: 1724−1725. doi: 10.1016/j.jacc.2006.01.042 [15] Reilly MM, Staunton H, Harding AE. Familial amyloid polyneuropathy (TTR ala 60) in north west Ireland: a clinical, genetic, and epidemiological study. J Neurol Neurosurg Psychiatry 1995; 59: 45−49. doi: 10.1136/jnnp.59.1.45 [16] Bonaïti B, Olsson M, Hellman U, et al. TTR familial amyloid polyneuropathy: does a mitochondrial polymorphism entirely explain the parent-of-origin difference in penetrance? Eur J Hum Genet 2010; 18: 948−952. doi: 10.1038/ejhg.2010.36 [17]

Waddington-Cruz M, Wixner J, Amass L, et al. THAOS investigators. Characteristics of patients with late- vs. early-onset Val30Met Transthyretin Amyloidosis from the Transthyretin Amyloidosis Outcomes Survey (THAOS). Neurol Ther 2021; 10: 753−766.

[18] Maurer MS, Hanna M, Grogan M, et al. THAOS Investigators. Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). J Am Coll Cardiol 2016; 68: 161−172. doi: 10.1016/j.jacc.2016.03.596 [19] Dungu JN, Valencia O, Pinney JH, et al. CMR-based differentiation of AL and ATTR cardiac amyloidosis. JACC Cardiovasc Imaging 2014; 7: 133−142. doi: 10.1016/j.jcmg.2013.08.015 [20] Griffin JM, Rosenblum H, Maurer MS. Pathophysiology and therapeutic approaches to cardiac amyloidosis. Circ Res 2021; 128: 1554−1575. doi: 10.1161/CIRCRESAHA.121.318187 [21]

Bukhari S, Oliveros E, Parekh H, et al. Epidemiology, mechanisms, and management of atrial fibrillation in cardiac amyloidosis. Curr Probl Cardiol 2022; 48: 101571.

[22] Oye M, Dhruva P, Kandah F, et al. Cardiac amyloid presenting as cardiogenic shock: case series. Eur Heart J Case Rep 2021; 5: ytab252. doi: 10.1093/ehjcr/ytab252 [23] Mueller PS, Edwards WD, Gertz MA. Symptomatic ischemic heart disease resulting from obstructive intramural coronary amyloidosis. Am J Med 2000; 109: 181−188. doi: 10.1016/S0002-9343(00)00471-X [24] Dorbala S, Vangala D, Bruyere J Jr, et al. Coronary microvascular dysfunction is related to abnormalities in myocardial structure and function in cardiac amyloidosis. JACC Heart Fail 2014; 2: 358−367. doi: 10.1016/j.jchf.2014.03.009 [25]

Nitsche C, Scully PR, Patel KP, et al. Prevalence and outcomes of concomitant aortic stenosis and cardiac amyloidosis. J Am Coll Cardiol 2021; 77: 128−139.

[26] Milandri A, Farioli A, Gagliardi C, et al. Carpal tunnel syndrome in cardiac amyloidosis: implications for early diagnosis and prognostic role across the spectrum of aetiologies. Eur J Heart Fail 2020; 22: 507−515. doi: 10.1002/ejhf.1742 [27] Sperry BW, Reyes BA, Ikram A, et al. Tenosynovial and cardiac amyloidosis in patients undergoing carpal tunnel release. J Am Coll Cardiol 2018; 72: 2040−2050. doi: 10.1016/j.jacc.2018.07.092 [28] Westin O, Fosbøl EL, Maurer MS et al. Screening for cardiac amyloidosis 5 to 15 years after surgery for bilateral carpal tunnel syndrome. J Am Coll Cardiol 2022; 80: 967−977. doi: 10.1016/j.jacc.2022.06.026 [29] Maurer MS, Smiley D, Simsolo E, et al. Analysis of lumbar spine stenosis specimens for identification of amyloid. J Am Geriatr Soc 2022; 70: 3538−3548. doi: 10.1111/jgs.17976 [30] Geller HI, Singh A, Alexander KM, et al. Association between ruptured distal biceps tendon and wild-type transthyretin cardiac amyloidosis. JAMA 2017; 318: 962−963. doi: 10.1001/jama.2017.9236 [31]

Rubin J, Alvarez J, Teruya S, et al. Hip and knee arthroplasty are common among patients with transthyretin cardiac amyloidosis, occurring years before cardiac amyloid diagnosis: can we identify affected patients earlier? Amyloid 2017; 24: 226−230.

[32] Dember LM. Amyloidosis-associated kidney disease. J Am Soc Nephrol 2006; 17: 3458−3471. doi: 10.1681/ASN.2006050460 [33] Sharma A, Bansal S, Jain R. Unique morphology of intratubular light chain casts in multiple myeloma: the amyloid cast nephropathy. Indian J Pathol Microbiol 2014; 57: 629−631. doi: 10.4103/0377-4929.142712 [34] Cipriani A, De Michieli L, Porcari A et al. Low QRS voltages in cardiac amyloidosis: clinical correlates and prognostic value. JACC Cardio Oncol 2022; 4: 458−470. doi: 10.1016/j.jaccao.2022.08.007 [35] Cyrille NB, Goldsmith J, Alvarez J, et al. Prevalence and prognostic significance of low QRS voltage among the three main types of cardiac amyloidosis. Am J Cardiol 2014; 114: 1089−1093. doi: 10.1016/j.amjcard.2014.07.026 [36] Dungu J, Sattianayagam PT, Whelan CJ, et al. The electrocardiographic features associated with cardiac amyloidosis of variant transthyretin isoleucine 122 type in Afro-Caribbean patients. Am Heart J 2012; 164: 72−79. doi: 10.1016/j.ahj.2012.04.013 [37] Murtagh B, Hammill SC, Gertz MA, et al. Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement. Am J Cardiol 2005; 95: 535−537. doi: 10.1016/j.amjcard.2004.10.028 [38] Das MK, Khan B, Jacob S et al. Significance of a fragmented QRS complex versus a Q wave in patients with coronary artery disease. Circulation 2006; 113: 2495−2501. doi: 10.1161/CIRCULATIONAHA.105.595892 [39] González-López E, Gagliardi C, Dominguez F, et al. Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths. Eur Heart J 2017; 38: 1895−1904. doi: 10.1093/eurheartj/ehx043 [40] Falk RH, Alexander KM, Liao R, et al. AL (Light-Chain) cardiac amyloidosis: a review of diagnosis and therapy. J Am Coll Cardiol 2016; 68: 1323−1341. doi: 10.1016/j.jacc.2016.06.053 [41] Nagy D, Révész K, Peskó G, et al. Cardiac amyloidosis with normal wall thickness: prevalence, clinical characteristics and outcome in a retrospective analysis. Biomedicines 2022; 10: 1765. doi: 10.3390/biomedicines10071765 [42]

Vermeer AMC, Janssen A, Boorsma PC, et al. Transthyretin amyloidosis: a phenocopy of hypertrophic cardiomyopathy. Amyloid 2017; 24: 87−91.

[43]

López-Sainz Á, de Haro-Del Moral FJ, Dominguez F, et al. Prevalence of cardiac amyloidosis among elderly patients with systolic heart failure or conduction disorders. Amyloid 2019; 26: 156−163.

[44]

Pagourelias ED, Mirea O, Duchenne J, et al. Echo parameters for differential diagnosis in cardiac amyloidosis: a head-to-head comparison of deformation and nondeformation parameters. Circ Cardiovasc Imaging 2017; 10: e005588.

[45] Phelan D, Collier P, Thavendiranathan P, et al. Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart 2012; 98: 1442−1448. doi: 10.1136/heartjnl-2012-302353 [46] Maceira AM, Joshi J, Prasad SK, et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 2005; 111: 186−193. doi: 10.1161/01.CIR.0000152819.97857.9D [47] Fontana M, Pica S, Reant P, et al. Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 2015; 132: 1570−1579. doi: 10.1161/CIRCULATIONAHA.115.016567 [48] Yang L, Krefting I, Gorovets A, et al. Nephrogenic systemic fibrosis and class labeling of gadolinium-based contrast agents by the Food and Drug Administration. Radiology 2012; 265: 248−253. doi: 10.1148/radiol.12112783 [49] Karamitsos TD, Piechnik SK, Banypersad SM, et al. Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging 2013; 6: 488−497. doi: 10.1016/j.jcmg.2012.11.013 [50] Banypersad SM, Fontana M, Maestrini V, et al. T1 mapping and survival in systemic light-chain amyloidosis. Eur Heart J 2015; 36: 244−251. doi: 10.1093/eurheartj/ehu444 [51] Martinez-Naharro A, Kotecha T, Norrington K, et al. Native T1 and extracellular volume in transthyretin amyloidosis. JACC Cardiovasc Imaging 2019; 12: 810−819. doi: 10.1016/j.jcmg.2018.02.006 [52]

Banypersad SM, Sado DM, Flett AS, et al. Quantification of myocardial extracellular volume fraction in systemic AL amyloidosis: an equilibrium contrast cardiovascular magnetic resonance study. Circ Cardiovasc Imaging 2013; 6: 34−39.

[53] Martinez-Naharro A, Abdel-Gadir A, Treibel TA, et al. CMR-verified regression of cardiac AL amyloid after chemotherapy. JACC Cardiovasc Imaging 2018; 11: 152−154. doi: 10.1016/j.jcmg.2017.02.012 [54] Kotecha T, Martinez-Naharro A, Treibel TA, et al. Myocardial edema and prognosis in amyloidosis. J Am Coll Cardiol 2018; 71: 2919−2931. doi: 10.1016/j.jacc.2018.03.536 [55] Rapezzi C, Gagliardi C, Milandri A. Analogies and disparities among scintigraphic bone tracers in the diagnosis of cardiac and non-cardiac ATTR amyloidosis. J Nucl Cardiol 2019; 26: 1638−1641. doi: 10.1007/s12350-018-1235-6 [56] Stats MA, Stone JR. Varying levels of small microcalcifications and macrophages in ATTR and AL cardiac amyloidosis: implications for utilizing nuclear medicine studies to subtype amyloidosis. Cardiovasc Pathol 2016; 25: 413−417. doi: 10.1016/j.carpath.2016.07.001 [57] Perugini E, Guidalotti PL, Salvi F, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3, 3-diphosphono-1, 2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol 2005; 46: 1076−1084. doi: 10.1016/j.jacc.2005.05.073 [58] Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 2016; 133: 2404−2412. doi: 10.1161/CIRCULATIONAHA.116.021612 [59] Bokhari S, Castaño A, Pozniakoff T, et al. (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging 2013; 6: 195−201. doi: 10.1161/CIRCIMAGING.112.000132 [60] Masri A, Bukhari S, Ahmad S, et al. Efficient 1-hour technetium-99 m pyrophosphate imaging protocol for the diagnosis of transthyretin cardiac amyloidosis. Circ Cardiovasc Imaging 2020; 13: e010249. doi: 10.1161/CIRCIMAGING.119.010249 [61] Falk RH, Lee VW, Rubinow A, et al. Sensitivity of technetium-99m-pyrophosphate scintigraphy in diagnosing cardiac amyloidosis. Am J Cardiol 1983; 51: 826−830. doi: 10.1016/S0002-9149(83)80140-4 [62] Musumeci MB, Cappelli F, Russo D, et al. Low sensitivity of bone scintigraphy in detecting Phe64Leu mutation-related transthyretin cardiac amyloidosis. JACC Cardiovasc Imaging 2020; 13: 1314−1321. doi: 10.1016/j.jcmg.2019.10.015 [63] Ardehali H, Qasim A, Cappola T, et al. Endomyocardial biopsy plays a role in diagnosing patients with unexplained cardiomyopathy. Am Heart J 2004; 147: 919−923. doi: 10.1016/j.ahj.2003.09.020 [64] Holzmann M, Nicko A, Kühl U, et al. Complication rate of right ventricular endomyocardial biopsy via the femoral approach: a retrospective and prospective study analyzing 3048 diagnostic procedures over an 11-year period. Circulation 2008; 118: 1722−1728. doi: 10.1161/CIRCULATIONAHA.107.743427 [65] Guy CD, Jones CK. Abdominal fat pad aspiration biopsy for tissue confirmation of systemic amyloidosis: specificity, positive predictive value, and diagnostic pitfalls. Diagn Cytopathol 2001; 24: 181−185. doi: 10.1002/1097-0339(200103)24:33.0.CO;2-D [66]

Takashio S, Yamamuro M, Izumiya Y, et al. Diagnostic utility of cardiac troponin T level in patients with cardiac amyloidosis. ESC Heart Fail 2018; 5: 27−35.

[67] Gillmore JD, Damy T, Fontana M, et al. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J 2018; 39: 2799−2806. doi: 10.1093/eurheartj/ehx589 [68] Dispenzieri A, Gertz MA, Kyle RA, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 2004; 22: 3751−3757. doi: 10.1200/JCO.2004.03.029 [69] Kumar S, Dispenzieri A, Lacy MQ, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 2012; 30: 989−995. doi: 10.1200/JCO.2011.38.5724 [70] Gilstrap LG, Dominici F, Wang Y, et al. Epidemiology of cardiac amyloidosis-associated heart failure hospitalizations among fee-for-service medicare beneficiaries in the United States. Circ Heart Fail 2019; 12: e005407. doi: 10.1161/CIRCHEARTFAILURE.118.005407 [71] Sperry BW, Saeed IM, Raza S, et al. Increasing rate of hospital admissions in patients with amyloidosis (from the National Inpatient Sample). Am J Cardiol 2019; 124: 1765−1769. doi: 10.1016/j.amjcard.2019.08.045 [72] Chan N, Hanna M, Maurer MS. The Wiggers Diagram: hemodynamic changes in cardiac amyloidosis. J Card Fail 2023; 29: 217−219. doi: 10.1016/j.cardfail.2022.06.008 [73] Gertz MA, Falk RH, Skinner M, et al. Worsening of congestive heart failure in amyloid heart disease treated by calcium channel-blocking agents. Am J Cardiol 1985; 55: 1645. doi: 10.1016/0002-9149(85)90995-6 [74] Gertz MA, Skinner M, Connors LH, et al. Selective binding of nifedipine to amyloid fibrils. Am J Cardiol 1985; 55: 1646. doi: 10.1016/0002-9149(85)90996-8 [75] Rubinow A, Skinner M, Cohen AS. Digoxin sensitivity in amyloid cardiomyopathy. Circulation 1981; 63: 1285−1288. doi: 10.1161/01.CIR.63.6.1285 [76] Muchtar E, Gertz MA, Kumar SK, et al. Digoxin use in systemic light-chain (AL) amyloidosis: contra-indicated or cautious use? Amyloid 2018; 25: 86−92. doi: 10.1080/13506129.2018.1449744 [77] Bukhari S, Khan SZ, Bashir Z. Atrial fibrillation, thromboembolic risk, and anticoagulation in cardiac amyloidosis: a review. J Card Fail 2023; 29: 76−86. doi: 10.1016/j.cardfail.2022.08.008 [78] Bukhari S, Barakat AF, Eisele YS, et al. Prevalence of atrial fibrillation and thromboembolic risk in wild-type transthyretin amyloid cardiomyopathy. Circulation 2021; 143: 1335−1337. doi: 10.1161/CIRCULATIONAHA.120.052136 [79]

El-Am EA, Dispenzieri A, Melduni RM, et al. Direct current cardioversion of atrial arrhythmias in adults with cardiac amyloidosis. J Am Coll Cardiol 2019; 73: 589−597.

[80]

Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2022; 145: e876−e894.

[81] Chung FP, Lin YJ, Kuo L, et al. Catheter ablation of ventricular tachycardia/fibri